Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 7:11:405-409.
doi: 10.2147/CEOR.S192910. eCollection 2019.

Abatacept: from a budget impact model to cost-effectiveness analysis - data from RCT and real life

Maurizio Benucci  1 , Arianna Damiani  1 , Mariangela Manfredi  2 , Maria Infantino  2 , Valentina Grossi  2 , Francesca Li Gobbi  1
Affiliations

Abatacept: from a budget impact model to cost-effectiveness analysis - data from RCT and real life

Maurizio Benucci et al. Clinicoecon Outcomes Res. .

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects joints with swelling and progressive joint destruction. The pathology leads to a progressive disability with an impact on the quality of life of the patients. Strategies to reduce in-patient care costs could have a considerable impact on lowering the direct medical costs of RA in Italy. Abatacept, a selective T-cell costimulation modulator, is a valuable treatment option for patients with moderate-to-severe RA. A search using the keywords "cost-effectiveness analysis", "budget impact model", "abatacept", and "rheumatoid arthritis" was carried out on PubMed. Abatacept in the first- and second-treatment lines has been evaluated in our research. We evaluated patients with inadequate MTX response, inadequate anti-TNF agents response, switch studies and real-world data. Furthermore, in our research, we evaluated the main head-to-head studies published.

Keywords: abatacept; budget impact model; cost-effectiveness analysis; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Similar articles

See all similar articles

References

    1. Scott DL, Steer S. The course of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):943–967. doi:10.1016/j.berh.2007.05.006 - DOI - PubMed
    1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108. doi:10.1016/S0140-6736(10)60826-4 - DOI - PubMed
    1. Lapadula G, Ferraccioli GF. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S102–S106. - PubMed
    1. Leardini G, Salaffi F, Montanelli R, et al. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol. 2002;20(4):505–515. - PubMed
    1. Benucci M, Rogai V, Atzeni F, Hammen V, Sarzi-Puttini PC, Migliore A. Costs associated with rheumatoid arthritis in Italy: past,presentand future. Clinicoecon Outcomes Res. 2016;8:33–41. doi:10.2147/CEOR.S91006 - DOI - PMC - PubMed